上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year 2024-07-10 13:30
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect 2024-01-25 08:30
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale 2023-11-22 13:21
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations 2023-05-22 16:30
WuXi Biologics Launches a New GMP Commercial Drug Product Facility 2021-11-01 10:19
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility 2021-07-26 18:00
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader 2020-02-18 18:42
WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader 2020-02-18 18:18
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany 2020-01-16 10:39
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland 2019-11-23 01:55
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu 2019-05-16 15:39
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership 2019-04-09 08:36
WuXi Biologics Receives EMA GMP Certificates 2019-03-20 08:07
WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland 2018-04-30 20:41
1